Ipatasertib, an oral AKT inhibitor, in combination with Bevacizumab exhibits anti-tumorigenic effects in pre-clinical studies for endometrioid endometrial cancer: Endometrial Cancer Molecularly Targeted Therapy Consortium
Publication
, Conference
Newton, M; Burkett, W; Zhao, Z; Secord, AA; Zhou, C; Bae-Jump, V
Published in: GYNECOLOGIC ONCOLOGY
2022
Duke Scholars
Published In
GYNECOLOGIC ONCOLOGY
EISSN
1095-6859
ISSN
0090-8258
Publication Date
2022
Volume
166
Start / End Page
S31 / S31
Related Subject Headings
- Oncology & Carcinogenesis
- 3215 Reproductive medicine
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1114 Paediatrics and Reproductive Medicine
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Newton, M., Burkett, W., Zhao, Z., Secord, A. A., Zhou, C., & Bae-Jump, V. (2022). Ipatasertib, an oral AKT inhibitor, in combination with Bevacizumab exhibits anti-tumorigenic effects in pre-clinical studies for endometrioid endometrial cancer: Endometrial Cancer Molecularly Targeted Therapy Consortium. In GYNECOLOGIC ONCOLOGY (Vol. 166, pp. S31–S31).
Newton, Meredith, Wesley Burkett, Ziyi Zhao, Angeles Alvarez Secord, Chunxiao Zhou, and Victoria Bae-Jump. “Ipatasertib, an oral AKT inhibitor, in combination with Bevacizumab exhibits anti-tumorigenic effects in pre-clinical studies for endometrioid endometrial cancer: Endometrial Cancer Molecularly Targeted Therapy Consortium.” In GYNECOLOGIC ONCOLOGY, 166:S31–S31, 2022.
Newton M, Burkett W, Zhao Z, Secord AA, Zhou C, Bae-Jump V. Ipatasertib, an oral AKT inhibitor, in combination with Bevacizumab exhibits anti-tumorigenic effects in pre-clinical studies for endometrioid endometrial cancer: Endometrial Cancer Molecularly Targeted Therapy Consortium. In: GYNECOLOGIC ONCOLOGY. 2022. p. S31–S31.
Newton, Meredith, et al. “Ipatasertib, an oral AKT inhibitor, in combination with Bevacizumab exhibits anti-tumorigenic effects in pre-clinical studies for endometrioid endometrial cancer: Endometrial Cancer Molecularly Targeted Therapy Consortium.” GYNECOLOGIC ONCOLOGY, vol. 166, 2022, pp. S31–S31.
Newton M, Burkett W, Zhao Z, Secord AA, Zhou C, Bae-Jump V. Ipatasertib, an oral AKT inhibitor, in combination with Bevacizumab exhibits anti-tumorigenic effects in pre-clinical studies for endometrioid endometrial cancer: Endometrial Cancer Molecularly Targeted Therapy Consortium. GYNECOLOGIC ONCOLOGY. 2022. p. S31–S31.
Published In
GYNECOLOGIC ONCOLOGY
EISSN
1095-6859
ISSN
0090-8258
Publication Date
2022
Volume
166
Start / End Page
S31 / S31
Related Subject Headings
- Oncology & Carcinogenesis
- 3215 Reproductive medicine
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1114 Paediatrics and Reproductive Medicine
- 1112 Oncology and Carcinogenesis